Navigation Links
Identification of 'fingerprint' of rare tumor leads to development of cheap and reliable new test
Date:5/19/2011

Researchers at the University of Oxford have developed a cheap and reliable diagnostic test for a rare form of cancer. The test involves screening tumour samples for a particular molecular fingerprint unique to this type of cancer.

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder which causes the development of benign but often painful tumours in the skin and, in females, in the uterus. Between one in six and one in ten people affected by the disorder will go on to develop an aggressive form of kidney cancer called papillary renal cell cancer. The condition often strikes people in their twenties.

The disorder is caused by mutations, which may be inherited, in a gene responsible for the production of an enzyme known as fumarate hydratase (FH). This leads to an accumulation within cells of fumarate, which promotes the development of cancer cells.

Now, in a study published in The Journal of Pathology, an international team of scientists led by researchers at the Henry Wellcome Building for Molecular Physiology, University of Oxford, have identified a particular protein modification which is induced by FH deficiency (and hence an over-abundance of fumarate). This alteration is unique to this type of tumour and can hence be used as a biomarker a biological 'fingerprint' to identify tumours caused by this mechanism.

The researchers have developed a test for this protein modification which can be carried out in less than two hours and will identify tumours with FH mutations. This approach is much more cost effective than genetic testing of all possible cases using DNA sequencing. They show that screening cases of papillary renal cell cancer using this new test allows them to identify undiagnosed cases of HLRCC for genetic testing. They believe this test should be applied to all cases of papillary renal cell cancer to identify those with FH mutations, allowing advice to be provided to their families on their own relative risks of developing the disorder and associated kidney cancer.

"Cancer can be caused by many different risk factors, but if we can pinpoint rapidly and accurately the particular type of tumour, we can provide more accurate advice to patients and their families, and perhaps diagnose cases at earlier, more treatable, stages," explains Dr Patrick Pollard, a Beit Memorial Fellow at the University of Oxford. "For the first time, we are now able to screen for tumours caused by this rare, but often very serious, condition using a test which is simple, cheap and reliable."

Dr Pollard and colleagues have filed a patent to develop the test, which is currently being marketed by Isis Innovation at the University of Oxford.

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: "We know that diagnosing cancer at an earlier stage offers the best chances of successful treatment. So being able to identify other family members who are at risk so they can be monitored more closely is crucial to improving survival rates from this rare aggressive form of kidney cancer.

"Tests like this can also help us to identify other patients with the same mutation, paving the way for the development of targeted treatments for specific groups of patients. This approach is called stratified medicine and many scientists now believe it could revolutionalise cancer treatment in the future."


'/>"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
Source:Eurekalert

Related medicine news :

1. New UC Davis study finds early Alzheimers identification method
2. New VKernel AppVIEW 1.0 for Monitoring and Identification of Capacity Bottlenecks in Critical Application VMs
3. Most Breast Tumors Have Unique Genetic Fingerprint, Study Finds
4. New diagnostic chip able to generate single-cell molecular fingerprints for brain tumors
5. Scientists Spot Genetic Fingerprints of Individual Cancers
6. Recurring cancers in women with a history of breast cancer differ from the original tumors
7. Mayo Clinic finds surgeon caseload, practice setting affect treatment of small kidney tumors
8. Brain Surgery for Mary Tyler Moore to Remove Benign Tumor
9. Stanford discoveries about tumor-suppressing protein could help to reduce treatment side effects
10. Scientists use genetically altered virus to get tumors to tattle on themselves
11. Strong evidence supports prognostic value of circulating tumor cells in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: